Journal
JOURNAL OF IMMUNOLOGY
Volume 180, Issue 6, Pages 3637-3641Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.180.6.3637
Keywords
-
Categories
Funding
- Intramural NIH HHS Funding Source: Medline
- NIDDK NIH HHS [U01 DK60352, U01 DK60349, U01 DK60346, R01 DK071560, U01 DK60309, U01 DK60324, U01 DK60327, U01 DK60329, U01 DK60335, U01 DK60345, U01 DK60344, U01 DK60342, U01 DK60341, U01 DK60340] Funding Source: Medline
Ask authors/readers for more resources
Up-regulation of programmed death-1 (PD-1) identifies exhausted T cells in various mouse and human viral models including chronic hepatitis C virus (HCV9 infection, which is characterized by impaired CTL function. A large proportion of patients fail to eradicate HCV with current IFN-based antiviral therapy; in particular, African Americans are less likely to respond, but the mechanisms for these differences are not fully elucidated. In this study, in 72 treatment-naive patients with persistent HCV we found that PD-1 was signficantly up-regulated on CD4(+) and CD8(+) Tcells, HCV-specific CTLs, and NK cells. Increased PD-1 on HCV-specific CTLs was significantly associated with failed early and sustained virologic response to therapy in African American hut not Caucasian American patients. Patients with sustained virologic response showed decreases in PD-1 on total CD4(+) T cells, HCV-specific CTLs, and the CD56(bright) NK subset after therapy completion. Collectively, these data indicate that PD-1 is critical in persistent HCV and successful therapy results in global down-regulation of its expression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available